Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer

Faecal microbiota transplantation increases activity of immunotherapy in mRCC

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma

Novel antibody drug conjugate TORL-1-23 shows preliminary antitumour activity in heavily-pretreated ovarian, endometrial, and testicular cancers

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

ESMO 2024: Latest in bladder cancer - expert review

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours

Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive ovarian cancer

ESMO 2024: Latest in EGFR mutated NSCLC

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer

ESMO 2024: Optimising the personalisation of prostate cancer treatment